SECOND AMENDMENT TO THE TECHNOLOGY COMMERCIALIZATION AGREEMENTTechnology Commercialization Agreement • September 25th, 2024 • Radiopharm Theranostics LTD • Pharmaceutical preparations
This Second Amendment (this “Second Amendment”), effective this 15th day of August, 2024 (the “Second Amendment Effective Date”), to the Technology Commercialization Agreement entered into by and among Board, MD Anderson and Company, dated September 9, 2022 (as amended by the Parties on June 20, 2023, the “Original Agreement”), is entered into by and among The Board of Regents of The University of Texas System (“Board”), an agency of the State of Texas, The University of Texas M. D. Anderson Cancer Center (“MD Anderson”) and Radiopharm Ventures, LLC (“Company”). Board, MD Anderson and Company may hereinafter be referred to collectively as the “Parties” or individually as a “Party.”
CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Technology Commercialization Agreement • September 25th, 2024 • Radiopharm Theranostics LTD • Pharmaceutical preparations
This Technology Commercialization Agreement (“Agreement”) is entered into this 9th day of September, 2022 (the “Effective Date”), by and among The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, The University of Texas M. D. Anderson Cancer Center (“MD Anderson”), a member institution of System, having a place of business located at 1515 Holcombe Blvd., Houston, Texas 77030 and Radiopharm Ventures, LLC, a Delaware limited liability company (“NewCo”) and a wholly-owned subsidiary of RadioPharm Theranostics (“RT”). MD Anderson and NewCo may each hereinafter be referred to individually as a “Party” and collectively as the “Parties.”
THIS TECHNOLOGY COMMERCIALIZATION AGREEMENT made as of the 1st of January, 2004.Technology Commercialization Agreement • May 19th, 2006 • Virexx Medical Corp • Biological products, (no disgnostic substances) • Alberta
WHEREAS the Foundation has approved for Funding the project entitled “A Phase I study of patients with primary or secondary cancers of the liver to determine the safety of Transcatheter Arterial Embolization and Hepclusin Injection” as more particularly described in the Application;
CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT WAS OMITTED BY MEANS OF MARKING SUCH INFORMATION WITH BRACKETS (“[***]”) BECAUSE THE IDENTIFIED CONFIDENTIAL INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR...Technology Commercialization Agreement • September 25th, 2024 • Radiopharm Theranostics LTD • Pharmaceutical preparations
This Amendment (“Amendment”) is made as of June 20, 2023 (the “Amendment Effective date”), by and among The Board of Regents (“Board”) of The University of Texas System, an agency of the State of Texas, The University of Texas M. D. Anderson Cancer Center (“MD Anderson”), and Radiopharm Ventures, LLC (“Company”). This Amendment amends the Technology Commercialization Agreement entered into by and among Board, MD Anderson, and Company, dated September 9, 2022 (the “Agreement”).
RECITALSTechnology Commercialization Agreement • May 4th, 2007 • NanoDynamics, Inc. • New York
